Via Oncology Publications


Mason C et al. Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting.
[Manuscript] J Clin Pathways 2017 4(1):49-54


Page R et al. Expanding indications of existing drugs and associated costs under risk reimbursement models.
[Abstract] J Clin Oncol 35, 2017 (suppl; abstr e18306)


Ellis PG et al. Using clinical pathways to understand biomarker testing patterns.
[Abstract] J Clin Oncol 35, 2017 (suppl; abstr e18189)


Ellis PG, O’Neil BH, Earle MF, et al. Clinical pathways: management of quality and cost in oncology networks in the metastatic colorectal cancer setting.
[Article] J Oncol Pract. 2017 Apr 5.


Ellis PG et al. Developing and piloting an electronic telephone triage application.
[Abstract] [Poster] J Clin Oncol 35, 2017 (suppl 8S; abstract 137)


Lokay K, Ellis PG.Impact of single dose vial size availability on drug costs.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl; abstr 6623)


Ellis PG et al. Impact of varying approaches used to compare costs between drug regimens.
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e18262)


Friedland D et al. Evaluating the impact of Via Pathways (VP) on the adoption of changing treatment paradigms in metastatic hormone-sensitive prostate cancer (mHSPC).
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e16510)


McCutcheon S et al. Frequency of efficacy, toxicity and cost as the deciding factor when determining clinical pathways
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e18169)


Ellis PG et al. Pathways Clinical Decision Support for Appropriate Use of Key Biomarkers.
[Article] JOP May 24, 2016 JOPR010546


Ellis PG, Weese JL. Clinical pathways as a platform to support clinical research.
[Abstract] [Poster] Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016 (ABSTR 2594)


Ellis PG et al. Actionable biomarkers in a non-small cell lung cancer (NSCLC) clinical pathway (CP).
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 155)


Heron DE et al. The benefits of clinical pathways (CP) for radiation oncology in a large cancer care network.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 148)


Heron DE et al. The standardization of skin cancer treatment recommendations through the analysis of clinical pathways data and an evidence-based, physician-driven committee process.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 147)


Ellis PG et al. The usefulness of clinical pathways (CP) in managing quality and cost in oncology networks.
[Abstract] [Poster] J Clin Oncol 34 (suppl 4S; abstr 715) 2016


Ellis PG et al. Incorporation of a patient question prompt list into a pancreatic cancer pathway.
[Abstract] J Clin Oncol 33 (suppl 29S; abstr 20) 2015


Ellis PG, Lokay K. Clinical pathways and quality metrics.
[Abstract] [Poster] J Clin Oncol 32 (suppl 30; abstr 273) 2014


Ellis PG, Lokay K. Pathways clinical decision support for appropriate use of key biomarker.
[Abstract] [Poster] J Clin Oncol 32 (suppl 30; abstr 172) 2014


Lokay K, Heron DE. Reducing unwarranted variability in care in radiation oncology through clinical pathways.
[Abstract] [Poster] J Clin Oncol 32 (suppl 30; abstr 171) 2014


Via Network Publications


Rodríguez-Lopéz JL, Ling DC, Heron DE, Beriwal S. Lag Time Between Evidence and Guidelines: Can Clinical Pathways Bridge the Gap?
[Article] JOP. December 2018:JOP.18.00430


Cost and survival analysis before and after implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer.
[Article] J Oncol Pract. 2017 Apr;13(4):e346-e352


Gebhardt BJ et al. Peer review process for implementation of clinical pathways (CP): Does it improve compliance?
[Abstract] Pract Radiat Oncol. 2017 Jan 19. pii: S1879-8500(17)30006-1. doi: 10.1016/j.prro.2017.01.006.


Insights From Building a New National Cancer Institute Community Oncology Research Program Site
[Article] J Clin Oncol 34, 2016 (suppl; abstr 6613)


Weese JL et al. Implementation of treatment pathways in a large integrated health care system.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl; abstr 6613)


Shamah CJ, Saphner TJ. Effect on clinical trial participation by integration of a clinical pathway program into an electronic health record (EHR).
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 167)


Shamah CJ et al. Integration of a clinical pathways software into an EHR in a large, multisite, hospital-affiliated community oncology setting.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 129)


Gebhardt BJ et al. Impact of dynamic changes to a bone metastases pathway in a large, integrated, National Cancer Institute-designated comprehensive cancer center network.
[Abstract] Pract Radiat Oncol. 2015 Nov-Dec;5(6):398-405


Rajagopalan MS et al. Changing practice patterns for breast cancer radiation therapy with clinical pathways: An analysis of hypofractionation in a large, integrated cancer center network.
[Abstract] Pract Radiat Oncol. 2015 Mar-Apr;5(2):63-9


Newcomer LN et al. Changing physician incentives for affordable, quality cancer care: results of an episode payment model.
[Abstract] J Oncol Pract. 2014 Sep;10(5):322-6


Tan S et al. Development and implementation of clinical pathways in lung cancer at an academic comprehensive cancer center.
[Abstract] [Poster] J Clin Oncol 32, 2014 (suppl 30; abstr 98)